Suppliers / Rosemont Pharmaceuticals

Rosemont Pharmaceuticals

United Kingdom 300 employees Updated 9 July 2026

Rosemont Pharmaceuticals is a finished-dose manufacturer based in United Kingdom. It appears in 242 regulatory filings across 8 regulators, without an active US DMF or CEP on file. Its filings concentrate with MHRA (UK), EMA and DMP (NO). Its GMP standing is certified by MHRA (UK). Its most recent recorded inspection, by US FDA, closed on 8 February 2019 as VAI.

0
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
242
filings across 8 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 8 February 2019 VAI US FDA
  • 12 December 2014 VAI US FDA
  • 13 October 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
LEEDS, United Kingdom Not on file
United Kingdom, United Kingdom 3002442738

Filings and GMP by regulator

Regulator Filings GMP certificates
MHRA (UK) 128 5
EMA 85 None
DMP (NO) 13 None
MPA (SE) 6 None
US FDA 4 None
SFDA (Saudi Arabia) 3 None

Comparing suppliers?

Choose your molecules and target markets. Rosemont Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 8 February 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates